Want to see ES:ATRY full AI Analyst Report?
ATRY Stock Chart & Stats
€3.01
-€0.02(-0.59%)
At close: 4:00 PM EST
€3.01
-€0.02(-0.59%)
Day’s Range― - ―
52-Week Range€2.31 - €3.59
Previous CloseN/A
Volume990.00
Average Volume (3M)83.73K
Market Cap
€188.43M
Enterprise Value€449.02M
Total Cash (Recent Filing)€17.76M
Total Debt (Recent Filing)€257.87M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding76,014,190
10 Day Avg. Volume190,561
30 Day Avg. Volume83,732
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.47
Price to Sales (P/S)1.58
P/FCF Ratio-15.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)€172.80M
Bulls Say, Bears Say
Bulls Say
Recurring Service RevenuesAtrys’s core revenue mix—radiation oncology treatments and diagnostic services sold to payers, hospitals and via service agreements—creates contractable, usage-driven cash flows. That recurring, payer-backed revenue base supports steady demand and predictability versus one-off sales.
Specialized Oncology And Diagnostics FocusConcentration on radiation oncology and diagnostics builds durable competitive advantages: clinical expertise, referral networks and technical capabilities. Specialization raises barriers to entry, supports higher gross margins historically, and underpins long-term demand from aging populations.
Manageable Historical LeverageHistorically moderate debt levels give Atrys some financial flexibility to fund operations or investments without severe leverage strain. This balance-sheet cushioning helps absorb near-term volatility and supports access to financing while management addresses profitability and cash generation issues.
Bears Say
Sharp 2025 Revenue DeclineA material revenue drop in 2025 reduces utilization of clinical assets and weakens operating leverage. If sustained, it pressures margins, complicates capacity planning and reduces cash available for reinvestment, making recovery and scale economies harder to achieve over the medium term.
Persistent Operating LossesConsistent negative EBIT indicates structural profitability problems: operating costs and headcount are not being covered by gross profit. Ongoing losses erode equity, limit ability to fund growth internally, and increase dependency on external financing or cost restructurings to restore profitability.
Recurring Negative Free Cash FlowChronic negative FCF signals persistent cash burn, forcing reliance on financing or balance-sheet actions to fund operations. This reduces resilience to shocks, constrains investment in expansion or technology, and raises dilution or refinancing risk if operating performance does not improve.
Atrys Health SA News
ATRY FAQ
What was Atrys Health SA’s price range in the past 12 months?
Atrys Health SA lowest stock price was €2.31 and its highest was €3.59 in the past 12 months.
What is Atrys Health SA’s market cap?
Atrys Health SA’s market cap is €188.43M.
When is Atrys Health SA’s upcoming earnings report date?
Atrys Health SA’s upcoming earnings report date is Aug 05, 2026 which is in 9 days.
How were Atrys Health SA’s earnings last quarter?
Currently, no data Available
Is Atrys Health SA overvalued?
According to Wall Street analysts Atrys Health SA’s price is currently Overvalued.
Does Atrys Health SA pay dividends?
Atrys Health SA does not currently pay dividends.
What is Atrys Health SA’s EPS estimate?
Atrys Health SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atrys Health SA have?
Atrys Health SA has 76,014,190 shares outstanding.
What happened to Atrys Health SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atrys Health SA?
Currently, no hedge funds are holding shares in ES:ATRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atrys Health SA
Atrys Health, S.A., a biomedical enterprise founded in 2007 and based in Madrid, Spain, specializes in providing a range of diagnostic services and medical treatments. Its diagnostic portfolio encompasses areas like pathology, hematology, molecular pathology, and genetics, supplemented by offerings such as diagnostic second opinions, a comprehensive test directory, and support for clinical trials and research & development. The company effectively utilizes telemedicine to deliver its expertise in medical specialties including radiology, cardiology, ophthalmology, and dermatology. Furthermore, Atrys Health administers radiotherapy and is engaged in the development of innovative therapeutic approaches and diagnostic instruments. The organization operated as Althia Health, S.L. before rebranding to Atrys Health, S.A. in May 2016.
Technical Analysis
Oryzon Genomics SA
―
Pharma Mar SA
―
1nKemia IUCT Group SA
―
PRIM, S.A.
―
Labiana Health SA
―